7642-58-2

Usage

Uses

Used in Pharmaceutical Industry:
(7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one is used as an anabolic steroid for promoting muscle growth and improving athletic performance. It is taken orally and has a rapid onset of action, making it popular among those seeking to enhance their physical abilities.
Used in Sports and Bodybuilding:
(7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one is used as a performance-enhancing drug by athletes and bodybuilders to increase muscle mass, strength, and endurance. Its anabolic effects contribute to improved physical performance and faster recovery from strenuous exercise.
However, it is important to note that the long-term use of (7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one can lead to various adverse effects, including liver damage, cardiovascular issues, and mood changes. Due to these potential risks, its use is regulated and restricted in many countries to ensure the safety and well-being of athletes and individuals using (7alpha,17beta)-17-hydroxy-7-methylandrost-4-en-3-one.

Upstream product

• 3591-23-9 6-dehydrotestosterone 
• 75-16-1 methylmagnesium bromide 
• 50880-57-4 RMI 12936 
• 58-22-0 testosterone 
• 40272-15-9 5α-Androst-6-en-3β,5,17β-triol-3,17-diacetat 
• 15084-43-2 Acetic acid (3S,7S,8R,9S,10R,13S,14S,17S)-17-acetoxy-7-iodomethyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl ester 
• 13890-57-8 3β,17β-Diacetoxy-7α-methyl-androst-5-en 
• 15825-36-2 7α-Methyl-androst-5-en-3β,17β-diol 

Relevant academic research and scientific papers

EMBODIMENTS OF MONOMER AND OLIGOMER COMPOUNDS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME

The invention relates to embodiments of monomer and oligomer compounds intended for use as contraceptive agents. The embodiments of monomer compounds of the present invention comprise substituents that facilitate the ability of the compounds to exhibit pr

Process for the production of 7alpha-methyl steroids

This invention relates to a process for the production of 7α-methyl steroids of general formula I, starting from compounds of general formula II, which are reacted in an aprotic solvent in the presence of 1-30 mol % of a copper compound CuYnLm with 1-3 molar equivalents of CH3MgX, then with a strong acid. The process according to the invention is distinguished in that 7α-methyl steroids are obtained in good yields as well as high chemical purity and high diastereomer purities. The process is distinguished in that less waste accumulates with considerably higher throughput. The process according to the invention can therefore be suitable for the production of 7α-methyl steroids on the industrial scale.

ANDROGEN AS A MALE CONTRACEPTIVE AND NON-CONTRACEPTIVE ANDROGEN REPLACEMENT

The present invention relates to methods of providing male contraception using a specified androgen without the need of a separate sterilizing agent. The invention also describes methods for non-contraceptive androgen replacement and devices useful for carrying out both processes.

TRANSDERMAL ADMINISTRATION OF MENT

The present invention relates to transdermal dosage forms for delivery of androgens.

Method for androgen supplementation

A particular group of androgens is not metabolized to their 5α-reduced form in the prostate and other tissues. Thus, administration of these compounds--testosterone derivatives with a non-hydrogen substituent in the 6α or 7α position--allows one to provide androgen supplementation therapy without stimulating abnormal prostate growth. A preferred compound for use in the invention is 7α-methyl-19-nortestosterone.